Absci's AI screens billions of cells each week, transitioning from antibodies to lab-validated candidates in six weeks. The company is currently involved in 17 active projects. AI is becoming increasingly important in the healthcare industry, with potential to significantly speed up innovative research and improve the accuracy of data analysis.
Key takeaways:
- AstraZeneca is partnering with US-based AI biologics firm, Absci, to design an antibody for cancer.
- The collaboration aims to create a zero-shot generative AI model to develop new antibody therapeutics for cancer and improve existing ones.
- AstraZeneca will invest up to $247 million in research and development, milestone payments and an upfront fee for Absci.
- AI is gaining momentum in the healthcare industry, with potential to significantly accelerate innovative research and improve the accuracy of data analysis.